risiko reduktion RRR var 31%; p= 0, 0001 med en absolut risiko på 7, 9% i placebogruppen og 5, 5% hos pravastatinbehandlede patienter); effekten på disse kumulative kardiovaskulære hændelsesrater var tydelige allerede efter 6 måneders behandling;
(relative risk reduction RRR was 31%; p = 0.0001 with an absolute risk of 7.9% in the placebo group, and 5.5% in pravastatin treated patients); the effects on these cumulative cardiovascular events rates being evident as early as 6 months of treatment;